Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMMIT-UC: Mirikizumab With or Without Tirzepatide in Ulcerative Colitis and Obesity/Overweight
2024-520209-38-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis, obesity and Overweight comparing Mirikizumab monotherapy, Mirikizumab + tirzepatide and Mirikizumab + placebo (3 arms). Primary endpoint: Simultaneous clinical remission and ≥10% weight reduction. Planned start Aug 2025; status: authorised.
02
Drugs
mirikizumabtirzepatide
03
Conditions
autoimmune colitisobesityOverweight
Beyond the preview
Go deeper on 2024-520209-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520209-38-00.